Welcome to our dedicated page for TransMedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on TransMedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics (TMDX) reported strong Q3 2024 financial results with total revenue of $108.8 million, representing a 64% increase from Q3 2023. The company achieved a net income of $4.2 million ($0.12 per diluted share), compared to a net loss in the previous year. Gross margin was 56%, down from 61% in Q3 2023. The company maintained its full-year 2024 revenue guidance of $425-445 million, projecting 76-84% growth. TransMedics owned 18 aircraft and held $330.1 million in cash as of September 30, 2024, continuing its progress toward the goal of 10,000 OCS transplant cases annually by 2028.
TransMedics Group, Inc. (Nasdaq: TMDX), a medical technology company focused on transforming organ transplant therapy, has announced that it will release its third quarter 2024 financial results after market close on Monday, October 28, 2024. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the results.
Investors can participate in the conference call by dialing (844) 481-2832 for domestic callers or (412) 317-1852 for international callers and requesting to join the TransMedics call. Additionally, a live and archived webcast of the event will be available on the company's investor relations website at https://investors.transmedics.com/.
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has granted inducement awards to a new employee. The grants, approved by the Compensation Committee, include:
- 336 non-qualified stock options with an exercise price of $156.00 per share
- 218 restricted stock units
The stock options will vest 25% after one year, with the remainder vesting monthly over three years. The restricted stock units will vest 25% annually over four years. Both grants are subject to continued employment and the terms of the TransMedics Group, Inc. Inducement Plan. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as material inducement for the employee's entry into employment with TransMedics.
TransMedics Group, Inc. (Nasdaq: TMDX), a medical technology company focused on transforming organ transplant therapy, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on Wednesday, September 4, 2024, at 1:05 p.m. Eastern Time at the Marriott Marquis New York.
Members of TransMedics' management team will engage in a fireside chat during the conference. Investors and interested parties can access a live and archived webcast of the discussion through the 'Investors' section of the TransMedics website. Additionally, the company's standard investor presentation is available for viewing on the same platform.
TransMedics Group, Inc. (Nasdaq: TMDX), a medical technology company focusing on organ transplant therapy, has announced the granting of inducement awards to four new employees. The grants, approved by the Compensation Committee and in line with Nasdaq Listing Rule 5635(c)(4), include:
- 3,073 non-qualified stock options with an exercise price of $170.28 per share
- 2,003 restricted stock units
The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over three years. The restricted stock units will vest 25% annually over four years. Both are subject to continued employment and the terms of the TransMedics Group, Inc. Inducement Plan.
TransMedics Group, Inc. (Nasdaq: TMDX) reported strong financial results for Q2 2024. Total revenue reached $114.3 million, a 118% increase from Q2 2023. The company generated a net income of $12.2 million or $0.35 per diluted share. Key highlights include:
- Owned 15 aircraft as of June 30, 2024, with two more purchased in July
- Published 2023 ESG update report
- Gross margin was 61%, down from 70% in Q2 2023
- Operating expenses increased to $56.8 million
- Cash position improved to $362.8 million
TransMedics raised its full-year 2024 revenue guidance to $425-$445 million, representing 76-84% growth compared to the previous year.
TransMedics Group (Nasdaq: TMDX), a medical technology company revolutionizing organ transplant therapy, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event will take place at the InterContinental Boston Hotel on Tuesday, August 13, 2024.
Key details of the presentation:
- Date: Tuesday, August 13, 2024
- Time: 9:30 a.m. Eastern Standard Time
- Location: InterContinental Boston Hotel
Investors and interested parties can access a live and archived webcast of the fireside chat through the 'Investors' section of the TransMedics website at https://investors.transmedics.com/.
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has granted inducement awards to 5 new employees. The awards include:
- 9,522 non-qualified stock options with an exercise price of $144.35
- 6,240 restricted stock units
These grants were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term and will vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly over the next 3 years. The restricted stock units will vest in 25% increments annually over 4 years. Both awards are subject to continued employment with TransMedics.
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on transforming organ transplant therapy, has announced its plans to release second quarter 2024 financial results on July 31, 2024, after market close. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the results. Investors can join the call by dialing (866) 807-9684 (domestic) or (412) 317-5415 (international) and requesting to join the TransMedics call. A live and archived webcast will be available on the company's investor relations website.
On June 18, 2024, TransMedics granted non-qualified stock options to purchase 1,002 shares of common stock and 657 restricted stock units (RSUs) to a new employee as a material inducement. These grants, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), are part of the TransMedics Inducement Plan. The stock options have an exercise price of $145.96 per share and a 10-year term. Vesting is structured with 25% of the shares vesting on the first anniversary of the employee's start date, and the remainder in equal monthly installments over three years. The RSUs follow a similar vesting schedule, with 25% vesting on the first four anniversaries of the employee's start date.